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RESEARCH

Open Access

Analyzing the impact of 23 mg/day donepezil on
language dysfunction in moderate to severe
Alzheimer’s disease
Steven H Ferris1*, Frederick A Schmitt2, Judith Saxton3, Sharon Richardson4, Joan Mackell5, Yijun Sun6 and
Yikang Xu7

Abstract
Introduction: Progressive language impairment is among the primary components of cognitive decline in
Alzheimer’s disease (AD). Because expressive and receptive language help to maintain emotional connections to
caregivers and support the management of AD patients’ functional needs, language plays a critical role in patients’
emotional and physical health. Using data from a large prospective clinical trial comparing two doses of donepezil
in patients with moderate to severe AD, we performed a post hoc analysis to determine whether a higher dose of
donepezil was associated with greater benefits in language function.
Methods: In the original randomized, double-blind clinical trial, 1,467 patients with moderate to severe AD
(baseline Mini-Mental State Examination (MMSE) score 0 to 20) were randomized 2:1 to receive donepezil 23
mg/day or to continue on donepezil 10 mg/day for 24 weeks. In this post hoc analysis, the Severe Impairment
Battery-Language scale (SIB-L) and a new 21-item SIB-derived language scale (SIB[lang]) were used to explore
differences in language function between the treatment groups. Correlations between SIB-L and SIB[lang] scores
and scores on the severe version of the Alzheimer’s Disease Cooperative Study-Activities of Daily Living
inventory (ADCS-ADL-sev), the Clinician’s Interview-Based Impression of Severity-plus caregiver input/Clinician’s
Interview-Based Impression of Change-plus caregiver input (CIBIS-plus/CIBIC-plus) and the MMSE were also
investigated.
Results: At week 24, treatment with donepezil 23 mg/day was associated with an improvement in language in the
full intention-to-treat population, whereas language function declined in the group treated with donepezil 10 mg/
day (SIB-L treatment difference 0.8, P = 0.0013; SIB[lang] treatment difference 0.8, P = 0.0009). Similar results were
observed in a cohort of patients with more severe baseline disease (MMSE score 0 to 16). At baseline and week 24,
correlations between the SIB-derived language scales and the ADCS-ADL-sev and CIBIC-plus were moderate, but
the correlations were stronger between the language scales and the MMSE scores.
Conclusions: Patients with moderate to severe AD receiving donepezil 23 mg/day showed greater language
benefits than those receiving donepezil 10 mg/day as measured by SIB-derived language assessments. Increasing
the dose of donepezil to 23 mg/day may provide language benefits in patients with moderate to severe AD, for
whom preservation of language abilities is especially critical.
ClinicalTrials.gov identifier: NCT00478205
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Introduction
An estimated 5.1 million Americans over 65 years of age
have Alzheimer’s disease (AD), and more than half of
these individuals are classified as having moderate or
severe disease [1]. As disease severity increases, patients
progressively lose the ability to communicate, express
their needs and participate in their accustomed relationships [2-4]. In patients with more advanced disease, this
often leads to an inability to sustain social relationships,
express needs for medical attention and relate or
respond to caregivers. Moreover, caregivers often
become frustrated by difficulties in understanding and
meeting patients’ loved ones’ needs, which can lead to
further patient distress [3,5-7]. The ability to use language to communicate helps to maintain emotional connections between the patient and his or her caregiver
and/or family, and loss of language ability is among the
most distressing factors associated with AD [3]. Thus,
treatment that can delay or even improve language abilities is an important focus of AD therapy.
Effective treatment of the loss of language abilities
presupposes the availability of reliable instruments for
evaluating such function. Commonly used tools such as
the Alzheimer’s Disease Assessment Scale-cognitive subscale, which is primarily a clinical trial measure developed to track the progression of AD symptoms [8], and
the Mini-Mental State Examination (MMSE) [9], which
is used in both clinical trials and clinical practice, are
valid and reliable measures of cognition and change in
cognitive function in less advanced stages of AD. However, when patients progress into the moderate to severe
stages of AD, these common tools are subject to a “floor
effect,” as they may become relatively insensitive to
changes in disease severity [10]. The Severe Impairment
Battery (SIB), originally developed more than 20 years
ago, was designed to assess cognition and changes in
cognitive function in patients with more advanced
impairment [11-14]. The SIB uses one-step conversational commands presented in conjunction with gestural
cues, enhancing its utility in patients with profound
impairments in communicative ability. The SIB remains
a reliable and sensitive assessment tool as patients progress along the continuum of moderate to severe AD,
and it is a widely used and validated measure of cognitive function in clinical trials [10,15-17].
Because of the centrality of language to cognitive
function, 24 of the 51 total items and subitems in the
full SIB scale assess language ability and comprise the
SIB language subscale [3]. In a previous study, a principal components factor analysis of these 24 items was
performed to determine which were the most relevant
in assessing language function [3]. Using baseline data
from patients enrolled in four placebo-controlled trials
of memantine, an N-methyl-D-aspartate receptor
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antagonist, in moderate to severe AD (baseline MMSE
score <15), 21 of the 24 items were found to have a factor loading >0.5 and were subsequently included in a
new language scale, the SIB Language scale (SIB-L).
Three of the twenty-four items had a factor loading <0.5
and were excluded from the SIB-L; the maximal SIB-L
score is 41. A subsequent post hoc analysis of data from
the same four trials, but which excluded patients who
did not have language deficits at baseline, demonstrated
significant differences on the SIB-L favoring active treatment over placebo, but SIB-L scores were decreased
compared with baseline in both treatment arms [18].
The cholinesterase inhibitor donepezil is the most frequently prescribed medication worldwide for the symptomatic treatment of mild, moderate and severe AD
[19,20]. Recently, a new dose of donepezil, a 23-mg
tablet, was approved by the US Food and Drug Administration for the treatment of moderate to severe AD.
Herein we report the results of a post hoc analysis of
data from a large, multinational, double-blind trial of
donepezil 23 mg/day versus donepezil 10 mg/day performed to determine whether treatment with higherdose donepezil is associated with benefits in language
abilities in patients with moderate to severe AD. Moreover, since previous reports have indicated that cognition and function may be interrelated in patients with
moderate to severe AD [21,22], we also evaluated relationships between measures of language function and
other instruments used to assess AD status.

Materials and methods
Study design

Detailed methods used in the original clinical trial have
been described previously [23]. In brief, this was a 24week, double-blind, parallel group trial including 1,467
patients with moderate to severe AD (baseline MMSE
scores 0 to 20 inclusive) who had been receiving a stable
dose of donepezil 10 mg/day for at least three months.
Patients were randomized in a 2:1 ratio either to an
increased donepezil dose of 23 mg/day or to continue
their preexisting donepezil 10 mg/day dose. The duration of treatment was 24 weeks. Coprimary efficacy
measures were change from baseline in SIB total score
(cognition) and the Clinician’s Interview-Based Impression of Change-plus caregiver input (CIBIC-plus; global
function) score at week 24. The protocol and informed
consent form for the original trial were approved by the
independent ethics committee and institutional review
board of each participating site and conformed to the
principles of the Declaration of Helsinki and all local
regulations. Written informed consent was obtained
from each participating patient, if possible, or from the
patient’s legal guardian or representative. If a patient
was unable to provide written consent, verbal assent to
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participate was required, with documentation of this
assent noted in the study record [23].
Scale construction

A new SIB-derived language scale, the 21-item Severe
Impairment Battery-derived language scale (SIB[lang]
scale), was constructed by performing a principal components factor analysis, similar to that employed in the creation of the SIB-L [3], on baseline scores of the 24-item SIB
language subscale in the full intention-to-treat (ITT)
population (see Additional File 1 for a listing of the 24
items in the SIB language subscale). Initial factors were
selected on the basis of eigenvalues >1. Selection of items
for inclusion in the SIB[lang] scale was based on a threshold of 0.5 for the single-item loading of each identified factor. Items with a factor loading <0.5 were deleted. In total,
21 of the 24 items in the SIB language subscale were identified as having a factor loading >0.5 and were included in
the SIB[lang] scale. Three items were excluded because of
a factor loading <0.5: free discourse, verbal comprehension
and repeating the word “baby.” As with the SIB-L scale,
scores on the SIB[lang] scale range from 0 to 41.
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ADCS-ADL-sev scale was analyzed both as a complete
unit and when separated into two subscales reflecting
basic and instrumental ADL abilities. Pearson correlation coefficients were calculated for baseline, week 24
and change from baseline scores. Because higher scores
on the SIB-derived language scales, the MMSE and the
ADCS-ADL-sev indicate less impairment, correlation
coefficients between these measures are positive. Since
higher scores on the CIBIS-plus/CIBIC-plus scales indicate greater impairment, correlation coefficients for relationships between SIB-L or SIB[lang] scores and CIBISplus/CIBIC-plus scores are negative.

Results
Patients

The full ITT population comprised 1,371 patients, 909
of whom received donepezil 23 mg/day and 462 of
whom received donepezil 10 mg/day. Demographics and
baseline disease characteristics were similar for both
donepezil treatment groups (Table 1), and no meaningful differences were observed between the groups in
relation to baseline scores on the SIB-derived language
scales (Table 2).

Post hoc analysis population

The post hoc language analyses were performed in the
full ITT population (all MMSE scores 0 to 20) and in a
cohort of patients with more severe baseline disease
(MMSE scores 0 to 16).

Table 1 Demographics and baseline characteristics in the
intention-to-treat populationa

Analysis of treatment effects

Age, years

Changes from baseline to week 24 in SIB-L and SIB
[lang] scale scores for the 23 mg/day and 10 mg/day
treatment groups were analyzed using an analysis of
covariance model with terms for baseline score, country
and treatment. For each end point, the least squares
(LS) or adjusted mean for each treatment group was calculated, as were between-treatment differences (donepezil 23 mg/day compared with donepezil 10 mg/day) in
adjusted means, 95% confidence intervals (95% CIs) for
the differences and the P values for the between-treatment differences. Summary statistics (median, mean,
standard deviation (SD), minimum, maximum and number of patients with nonmissing data) at week 24 using
last observation carried forward and observed cases are
provided by treatment group.

Number of patients

Characteristics

Mean (±SD)
Gender
Number of patients

Donepezil
23 mg/day

Donepezil
10 mg/day

909

462

73.8 (8.48)

73.8 (8.55)

909

462

Males, n (%)

335 (36.9%)

175 (37.9%)

Females, n (%)

574 (63.1%)

287 (62.1%)

MMSE
Number of patients
Mean (±SD)

908

462

13.1 (4.99)

13.1 (4.72)

908
34.1 (10.88)

461
34.5 (11.19)

ADCS-ADL-sev total
Number of patients
Mean (±SD)
SIB
Number of patients
Mean (±SD)

907

462

74.2 (17.58)

75.6 (16.28)

CIBIS-plus

Analysis of correlations between outcome measures

Number of patients

Relationships between SIB-L and SIB[lang] scale scores
and scores on the MMSE, the Clinician’s InterviewBased Impression of Severity-plus caregiver input
(CIBIS-plus; the baseline version of the CIBIC-plus
assessment tool) and CIBIC-plus, and the severe version
of the Alzheimer’s Disease Cooperative Study-Activities
of Daily Living (ADCS-ADL-sev) were examined. The

Mean (±SD)
Concomitant memantine use
Number of patients
Using memantine, n (%)

904

461

4.42 (0.85)

4.38 (0.89)

909

462

338 (37.2)

163 (35.3)

a
MMSE = Mini-Mental State Examination; ADCS-ADL-sev = Alzheimer’s Disease
Cooperative Study-Activities of Daily Living inventory, severe version; SIB =
Severe Impairment Battery; CIBIS-plus = Clinician’s Interview-Based Impression
of Severity-plus caregiver input; SD = standard deviation.
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Table 2 Baseline scores on SIB-derived language scales in the ITT populationa
MMSE score

SIB-L

SIB[lang]

Donepezil 23 mg/day

Donepezil 10 mg/day

Donepezil 23 mg/day

Donepezil 10 mg/day

0 to 20b

32.4 ± 8.2
(n = 907)

32.9 ± 7.7
(n = 462)

31.4 ± 8.3
(n = 907)

31.9 ± 7.7
(n = 462)

0 to 16

30.5 ± 8.9
(n = 641)

31.2 ± 8.3
(n = 331 )

29.5 ± 9.0
(n = 641)

30.3 ± 8.4
(n = 331)

a
SIB = Severe Impairment Battery; ITT = intention to treat; MMSE = Mini-Mental State Examination; SIB-L = Severe Impairment Battery-Language scale; SIB[lang] =
21-item Severe Impairment Battery-derived language scale; bfull ITT population. Data are means ± SD.

Study coprimary end points

As previously reported, the change from baseline in SIB
scores at week 24 showed significant improvement in
cognition associated with treatment with donepezil 23
mg/day relative to treatment with donepezil 10 mg/day
(LS mean score change 2.6 versus 0.4, treatment difference 2.2; P < 0.001) [23]. Treatment difference in global
function as measured by the CIBIC-plus scale numerically favored donepezil 23 mg/day but was not statistically significant.

weak correlations with baseline assessments for the
other measures.

Discussion
The already fragile relationships in the lives of patients
with AD can become profoundly disrupted as patients
lose the ability to communicate coherently. Attachment
to caregivers and others becomes compromised, and the
effect of such detachment on caregivers can be deleterious. Furthermore, it is difficult for clinicians and

Post hoc analysis: treatment effects

Changes in SIB-L and SIB[lang] scores from baseline to
week 24 are shown in Figure 1. For both language
assessments, donepezil 23 mg/day was associated with
improvement in language function in the full ITT population as well as in the MMSE scale 0 to 16 score
cohort. Regardless of the language assessment used,
treatment with donepezil 10 mg/day was associated with
a mean decline in language function in both the full
ITT and MMSE scale 0 to 16 score cohort. Treatment
differences between donepezil 23 mg/day and donepezil
10 mg/day were statistically significant in all analyses
(Figure 1).
Post hoc analysis: correlations

At baseline, SIB-L and SIB[lang] scores were moderately
correlated with scores on the ADCS-ADL-sev (r ≈ 0.5)
and CIBIS-plus (r ≈ -0.5) (Table 3). Baseline correlations
between SIB-L and SIB[lang] scores and scores on the
MMSE were strong (r ≈ 0.7).
At week 24, correlations between SIB-L and SIB[lang]
scores and scores on the ADCS-ADL-sev and MMSE
were marginally but consistently stronger than at baseline (Table 3). In contrast, correlations between scores
on the SIB-derived language scales and CIBIS-plus/
CIBIC-plus scores were weaker at week 24 than at
baseline.
Correlations between change from baseline in SIB-L
and SIB[lang] scores and change from baseline in scores
on other assessments were generally of weak to moderate strength, with the MMSE scores showing the strongest correlation (Table 3). Likewise, change from
baseline in SIB-L and SIB[lang] scores showed only

Figure 1 Least squares (LS) mean change from baseline to
week 24 in Severe Impairment Battery-Language scale (SIB-L)
scores (A) and 21-item Severe Impairment Battery-derived
language scale (SIB[lang]) scores (B). MMSE = Mini-Mental State
Examination; SE = standard error of the mean.
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Table 3 Correlations between SIB-L and SIB[lang] scores and scores on the ADCS-ADL-sev (total, basic and
instrumental), CIBIS/CIBIC-plus and MMSE (full ITT population)a
SIB-L
AD scales

Baseline

Week 24

SIB[lang]

Change from baseline

Baseline

0.1497

0.5250

Week 24

Change from baseline

ADCS-ADL-sev total
Baseline
Week 24

0.5268
0.5820

Change from baseline

0.1418
0.5777

0.2837

0.2912

ADCS-ADL-sev basic
Baseline

0.5214

Week 24

0.1124

0.5193

0.5669

Change from baseline

0.1036
0.5621

0.2643

0.2695

ADCS-ADL-sev instrumental
Baseline
Week 24

0.4745

0.1546

0.4730

0.5400

Change from baseline

0.1481
0.5365

0.2369

0.2441

CIBIS-plus/CIBIC-plus
Baseline (CIBIS-plus)

-0.5100

Week 24 (CIBIC-plus)

-0.1722

-0.5117

-0.1918

Change from baseline (CIBIC-plus)

-0.1821
-0.1891

-0.3484

-0.3493

MMSE
Baseline
Week 24

0.7208

0.2205
0.7375

Change from baseline

0.7183

0.2359
0.7394

0.3618

0.3517

a

SIB-L = Severe Impairment Battery-Language scale; SIB[lang] = 21-item Severe Impairment Battery-derived language scale; ADCS-ADL-sev = Alzheimer’s Disease
Cooperative Study-Activities of Daily Living inventory, severe version; CIBIS-plus = Clinician’s Interview-Based Impression of Severity-plus caregiver input; CIBICplus = Clinician’s Interview-Based Impression of Change-plus caregiver input; MMSE = Mini-Mental State Examination; ITT = intention to treat; n values for
individual correlation coefficients ranged from 1,363 to 1,371. All correlations were statistically significant (P ≤ 0.0001).

caregivers to render optimal care in the absence of clear
input from patients regarding what they are feeling or
concerned about. When language comprehension deteriorates, it is also likely to further increase caregiving
stress, as patients have difficulty understanding conversation and even simple directions. Moreover, decline in
language is associated with increased risk of mortality
[24]. Therefore, therapy to slow or reduce the loss of
language abilities has the potential to result in additional
quality time for patients and caregivers alike.
In the primary study of donepezil 23 mg/day versus donepezil 10 mg/day, patients treated with donepezil 23 mg/day
showed significant improvement in cognition, as measured
by the SIB, compared with patients taking donepezil 10 mg/
day [23]. Notably, SIB total scores at week 24 were
improved relative to baseline scores in the donepezil 23 mg/
day group, indicating that there was no measurable decline
in cognition over the six months of treatment. In this post
hoc analysis, we found that treatment with donepezil 23 mg/
day resulted in significant improvement in language ability
compared with donepezil 10 mg/day in patients with moderate to severe AD as measured by the two SIB-derived language scales: the SIB-L, and the SIB[lang].
Since the SIB-L was derived using data from a population of patients with baseline MMSE scores <15 enrolled

in studies of memantine versus placebo [3], there was a
possibility that this scale would not be suitable for the
measurement of language function in the current analysis, as this patient population had differing baseline
characteristics and demographics. Therefore, the SIB
[lang] scale was created by performing a factor analysis
of baseline SIB language subscale scores in the full ITT
population from the study of donepezil 23 mg/day versus donepezil 10 mg/day. As was the case in the creation of the SIB-L [3], the SIB[lang] scale comprised 21
of the 24 items in the SIB language subscale, with three
items excluded. However, while the free discourse item
was excluded from both scales, the other two items
eliminated in the creation of the SIB[lang] scale (verbal
comprehension and repeating the word “baby”) were different from those excluded from the original SIB-L
(forced choice naming, cup and shape identification,
square). This suggests that the results of the two factor
analyses were somewhat study population-driven, likely
reflecting AD severity as well as cultural influences on
language assessment. Nevertheless, the fact that the SIBL and SIB[lang] scales showed equivalent performance
in the current analysis demonstrates that the utility of
these language scales extends beyond the specific patient
populations from which they are derived.
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The findings of this post hoc language analysis have
important clinical implications. One is to support the
assertion that language and the ability to communicate
can be reliably and easily assessed in patients with moderate to severe AD using SIB-derived language scales. Of
potentially greater importance is the finding that not
only were substantial incremental benefits in language
ability achieved with donepezil 23 mg/day treatment
beyond those achieved with donepezil 10 mg/day, but
also the benefits were evident in both the full study
population (MMSE scores 0 to 20) and the cohort of
patients with more severe baseline disease (MMSE
scores 0 to 16). Indeed, in both analysis populations, the
donepezil 23 mg/day treatment group showed improvements in language function above baseline performance
levels after six months of treatment, whereas the donepezil 10 mg/day group showed declines in language
function. This suggests that the donepezil 23 mg/day
dose may help to preserve language abilities in patients
as they move across the spectrum of moderate to severe
AD.
Why the donepezil 23 mg/day dose should have a
greater effect on language function as compared with
the donepezil 10 mg/day dose was not investigated in
this analysis. However, one could speculate that the
observed outcomes may be due to the higher dose of
donepezil providing greater enhancement of cholinergic
function in regions of the brain controlling speech and
language. Another hypothetical scenario is that the
observed language benefits are driven in whole or in
part by enhanced effects of the 23 mg/day dose on
regions of the brain controlling other cognitive processes, such as attention and memory. Indeed, it is logical that attention deficits could substantially influence a
patient’s language ability as measured by the SIB-L and
SIB[lang] scales. Moreover, there is clearly some overlap
between certain aspects of language impairment, such as
word-finding difficulty, and more general memory
retrieval problems. Nevertheless, the items included in
the SIB-L and SIB[lang] scales cover a broad range of
language functions, including processes that are not
highly dependent on memory, and, as such, treatment
effects on memory are likely to account for a relatively
small portion of the observed language improvements.
Ultimately, the direct and indirect mechanisms whereby
donepezil 23 mg/day provides improved language benefits over the donepezil 10 mg/day dose need to be determined in adequately designed prospective studies.
Language effects of other pharmacologic treatments
for AD have varied in studies of patients with moderate
to severe disease. For example, in an analysis of pooled
data from four memantine trials in patients with moderate to severe AD (MMSE score <15), mean SIB-L score
changes from baseline through week 24 or week 28
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were significantly better for those receiving the active
treatment compared with placebo, but mean SIB-L
scores declined in both treatment groups [18]. Likewise,
in a post hoc analysis of the specific language effects of
memantine in patients with moderate to severe AD
(MMSE scores 3 to 14) enrolled in six clinical trials,
memantine was associated with significantly better SIB
language subscale scores compared with placebo; however, scores in both groups declined from baseline to
the end of the study (six months) [25]. In addition, in a
cohort of patients with severe AD (MMSE scores 5 to
12) treated with the cholinesterase inhibitor galantamine
for 26 weeks, mean SIB language subscale scores were
numerically improved at the end point, but improvement over placebo was not statistically significant [26].
Not surprisingly, the MMSE, a measure of cognition
that includes several language items, showed the strongest correlation with SIB-L and SIB[lang] scores for all
relationships explored. However, correlations between
the language scales and the MMSE were substantially
stronger for baseline and week 24 scores (r ≈ 0.7) than
for change from baseline scores (r ≈ 0.35). This suggests
that cognition as measured by the MMSE is strongly
related to language abilities as measured by SIB-derived
language scales, but that changes in cognition on the
MMSE and changes in language on the SIB language
scales track differently over time. Pearson correlation
coefficients also showed that baseline SIB-L and SIB
[lang] scores were moderately correlated with baseline
scores for the ADCS-ADL-sev and CIBIS-plus, suggesting that language abilities and functional abilities may
be interrelated in the moderate to severe AD population.
However, correlations for change from baseline scores
were only of moderate to weak strength. As Farlow and
colleagues [23] previously reported, changes in ADCSADL-sev scores and CIBIC-plus scores in this study
were small. Coupled with the limitations of these classes
of instruments, this may at least in part explain the
absence of stronger correlations. It is also noteworthy
that changes from baseline to week 24 in SIB-L and SIB
[lang] scores were only weakly correlated with baseline
scores on the ADCS-ADL-sev, CIBIS-plus and MMSE.
This suggests that there is little relationship between
baseline functional or cognitive status and treatmentmediated changes in language abilities; thus, patients
with AD may achieve meaningful language benefits with
treatment, irrespective of the degree of functional or
cognitive impairment. Since the correlation findings are
from a post hoc analysis, they will need to be corroborated in prospective studies.

Conclusions
The results of this analysis suggest that donepezil 23
mg/day may result in improvements in the critical factor
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of language in advanced AD as measured by SIB-derived
language scales. These findings indicate that increasing
the dose of donepezil to 23 mg/day may provide language benefits in patients with moderate to severe AD,
for whom preservation of language abilities is especially
critical. Supporting communication in patients with a
progressive disease such as AD may have the potential,
even in advanced stages of AD, to improve patients’
quality of life and reduce the burden of AD experienced
by caregivers.

Additional material
Additional file 1: Items in the SIB Language Subscale. A table listing
the 24 items in the Severe Impairment Battery (SIB) language subscale.
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